- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Milestone Pharmaceuticals Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 17.04. | Milestone Pharmaceuticals Inc.: Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium | 2 | GlobeNewswire (USA) | ||
| 08.04. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.04. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting | 71 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 01.04. | Milestone Pharmaceuticals Inc.: Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences | 3 | GlobeNewswire (USA) | ||
| 28.03. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | Milestone Pharmaceuticals reports Q4 results | 2 | Seeking Alpha | ||
| 21.03. | Milestone Pharmaceuticals: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 21.03. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update | 127 | GlobeNewswire (Europe) | - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting... ► Artikel lesen | |
| 21.03. | Milestone Pharmaceuticals Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Piper Sandler cuts Milestone Pharma stock target to $5, keeps Overweight | 8 | Investing.com | ||
| 04.03. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 29.02. | Milestone Pharmaceuticals Inc.: Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference | 2 | GlobeNewswire (USA) | ||
| 29.02. | Milestone Pharma slides on deep-discounted stock offering | 1 | Reuters | ||
| 29.02. | Milestone Pharmaceuticals sets public offering at $1.50 per share | 1 | Investing.com | ||
| 29.02. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 28.02. | Milestone Pharmaceuticals launches stock and warrants offering | 1 | Seeking Alpha | ||
| 28.02. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 26.02. | Milestone Pharma up on plans to resubmit FDA application for heart drug | 3 | Reuters |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK & CO | 121,00 | -0,33 % | Erfolg auf ganzer Linie: Die Kasse klingelt bei Merck & Co.: Pharmariese hebt Umsatzprognose für 2024 an! | © Foto: © 2023 Merck & CoMerck hat am Donnerstag positive Ergebnisse vorgelegt, die die Markterwartungen übertrafen. Dies ist auf robuste Umsätze mit seinem Krebsmedikament Keytruda und eine hohe Nachfrage... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 8,750 | +2,34 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 12,100 | +0,83 % | Assembly Biosciences: CEO begeistert von "außergewöhnlichen Fortschritten" | Zusammen mit der Einladung zur Hauptversammlung am 29. Mai präsentierte Assembly Biosciences (WKN: A402CB) gestern seinen aktuellen Geschäftsbericht im Hochglanz-Format. In einem Anschreiben an Aktionäre... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 7,880 | -0,25 % | Newron Pharma: Chavez wird neue Verwaltungsrätin | Bei Newron Pharma gibt es eine - allerdings erwartete - Veränderung im Verwaltungsrat. Auf der Hauptversammlung des italienischen Biotech-Unternehmens wurde Margarita Chavez neu in das Gremium gewählt.... ► Artikel lesen | |
| ALTIMMUNE | 5,920 | -0,75 % | Guggenheim downgrades Altimmune as 'ship has likely sailed' for obesity drug | ||
| ROCKET LAB USA | 3,520 | -0,85 % | Rocket Lab USA prepares Electron launches to deploy NASA's PREFIRE mission | ||
| BOIRON | 34,100 | +0,74 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| MEDICINOVA | 1,250 | 0,00 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,140 | +0,99 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,735 | 0,00 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
| HARROW | 10,620 | +0,85 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| SHINECO | 0,762 | 0,00 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Charge Enterprises, Inc. and others from The Nasdaq Stock Market | NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of NanoString Technologies, Inc. NanoString Technologies, Inc.'s securities... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,630 | -7,91 % | CUMBERLAND PHARMACEUTICALS INC - 8-K, Current Report | ||
| REVIVA PHARMACEUTICALS | 2,900 | -3,01 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen |
MILESTONE PHARMACEUTICALS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,570 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
